Learn about clinical trials that are currently recruiting.

— Phase 3 NASH Study
— Phase 4 PBC Study
— Phase 2 Biliary Atresia Study

WE SEE YOU

At Intercept, our work is motivated by our desire to help patients and families who struggle with chronic liver diseases and need better treatment options.

Partnering

INT-777 (6alpha-ethyl-23(S)-methyl-cholic acid, 6-EMCA) is an orally administered TGR5 agonist that is derived from the primary human bile acid cholic acid. Our in vitro studies have shown that INT-777 has the potential to selectively target TGR5, a G-protein coupled receptor that has been shown to directly regulate the release of glucagon-like peptide-1, or GLP-1, in the intestine with resulting insulin-sensitizing effects. We have completed the preclinical studies necessary for the filing of an IND. We own exclusive worldwide, royalty-free rights to INT-777.

In vitro studies have shown that INT-777 has the potential to

  • Control glucose homeostasis
  • Inhibit atherosclerosis by reducing macrophage inflammation and lipid loading
  • Prevent diabetic kidney disease

Contact: All partnering inquiries should be directed to Senthil Sundaram, Corporate Development.


Current collaborationsa

Sumitomo Dainippon Pharma Co. Ltd.

In March 2011, Intercept entered into a license agreement with Sumitomo Dainippon Pharma Co. Ltd. Sumitomo Dainippon has an exclusive license to research, develop, and commercialize obeticholic acid (OCA) as a therapeutic for the treatment of primary biliary cirrhosis* (PBC) and nonalcoholic steatohepatitis (NASH) in Japan, China (excluding Taiwan), and Korea. We granted Sumitomo Dainippon an option under the agreement to obtain an exclusive license to commercialize OCA for indications other than PBC and NASH on the same terms as are set forth in the agreement.

Servier

In August 2011, Intercept entered into a research, development, license, and commercialization agreement with Les Laboratories Servier and Institut De Recherches Servier (Servier), under which we granted Servier the exclusive license to research, develop, and commercialize novel TGR5 agonists (other than INT-767 and INT-777) for use in the treatment of diabetes, obesity, atherosclerosis, and reperfusion injury in all countries other than the United States and Japan, and Servier granted us an exclusive royalty-free license to research and develop such compounds for use in the treatment of diabetes, obesity, atherosclerosis, and reperfusion injury in the United States and Japan.

aNote: please review our documents filed with the SEC for a complete and comprehensive disclosure of our strategic collaborations and research arrangements.

*Also known as primary biliary cholangitis.

You are now leaving interceptpharma.com


You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Intercept provides this link as a service to its website visitors. Intercept is not responsible for the content or the privacy policy of any third party websites.

Close this window to return to Intercept Pharma’s site or click ‘Continue’ to proceed. 

You are now being redirected to Intercept's job application site, hosted by a third party.